
    
      ICC(Intrahepatic CholangioCarcinoma) patients with metastasis has a short survival time and
      poor prognosis after diagnosis. Treatment methods was few and far from satisfaction. The
      treatment recommended from NCCN guideline was GEMOX(Systemic Chemotheray) and clinical
      trials. Our previous study has demonstrate FOLFOX (Systemic Chemotheray based on
      Oxaliplatin#5- fluorouracil) has a similar survival and tumor response compared with GEMOX.
      Further study was needed to intensive confirmation of the result. We designed this study to
      demonstrate the hypothesis. Metastasis ICCs were recruited and screened by our criteria. All
      patients were treated with FOLFOX (Systemic Chemotheray based on Oxaliplatin#5-fluorouracil
      ), apatinib (one of tyrosine kinase inhibitors) plus sintilimab (one of PD-1 antibody).

      Our study were designed to verify the better method of survival for metastatic ICC.
    
  